

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Norihiro NISHIMOTO et al.

Title: A PREVENTIVE AGENT FOR
VASCULITIS

Appl. No.: 10/596,429

International 12/17/2004

Filing Date:

371(c) Date: 06/13/06

Examiner: Unassigned

Art Unit: Unassigned

Confirmation 6508

Number:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English or have English translations.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date August 7, 2006

By Michael D. Kaminski
Reg. No. 32,904

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

Harold C. Wegner
Attorney for Applicant
Registration No. 25,258

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/596,429
Date Submitted: August 3, 2006 <i>(use as many sheets as necessary)</i>				Filing Date	12/17/2004
				First Named Inventor	Norihiro NISHIMOTO
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	053466-0417

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
A1	JP	10324639	A	Mihara MASAHIKO	12/08/1998	Abstract		
A2	JP	2003026699	A	Yoshizaki KAZUYUKI et al.	01/29/2003	Abstract		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B1	Hiroshi HASHIMOTO, "Surveillance Study on Intractable Angitis Comprehensive Research Report in a Financial Year", Heisei 13, March 2002, pp. 47-55, full text with translation.	
	B2	Shunsei HIROHATA et al., "Elevation of Cerebrospinal Fluid Interleukin-6 Activity in Patients with Vasculitides and Central Nervous System Involvement", Clinical Immunology and Immunopathology, Vol. 66, No. 3, March, pp. 225-229, 1993.	
	B3	Marina NORIS et al., "Interleukin-6 and RANTES in Takayasu Arteritis", Circulation, July 6, 1999, pp. 55-60.	
	B4	Norihiro NISHIMOTO, "Approach for Therapy in the Near Future –Focusing around the Anti-Cytokine Therapy", medicina, vol. 38, No. 3, March 2001, pp.441-445, full text with translation.	
	B5	Ryuji KOIKE, "Systemic erythematosus (SLE) and antiphospholipid antibody syndrome", medicina, vol. 35, no. 10, October 1998, pp. 1728-1730, full text with translation.	
	B6	International Search Report	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.